Nisin Z and Lacticin 3147 Improve Efficacy of Antibiotics Against Clinically Significant Bacteria

Ellis, Jenna-Claire; Ross, R. Paul; Hill, Colin

doi:10.2217/fmb-2019-0153

Cited by 27 publications

(17 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…decreased the count of the gram positive Staphylococcus sciuri, while Escherichia coli, molds and yeasts were increased. The great activity of this bacteriocin; Nisin was recorded by many researchers [27][28][29][30][31]. The arising count of gram negative bacteria and mycotic growth may be organized by the nutritional competition among microbial populations [32].…”

Section: Discussionmentioning

confidence: 98%

Application of Lactobacillus helveticus CNRZ 32 to Control the Microbial Contaminants in Cheese by Addition of Bacterial Extracts or by In Situ Production of Bioactive Metabolites

El-Sayad¹,

Ibrahim²,

Sharaf³

et al. 2021

AJC

View full text Add to dashboard Cite

Microbial spoilage of cheese represents a major concern from both health and economic views. The addition of food preservatives is considered the most applied strategy to ensure food quality and to control microbial contamination. It well established that natural preservatives such as Nisin and Natamycin are of great effectiveness against a wide range of microbial concerns, but the lack of wide spectrum effect induces looking for more efficient alternatives. This research suggests alternative treatments to be evaluated side by side with both Nisin and Natamycin within real cheese models to control microbial contamination during the storage period. To evaluate this, two varieties of cheese were manufactured and inoculated with a set of pathogen and cheese spoiling microorganisms. Talaga cheese batches were separately treated with extract of MRS that previously fermented by Lactobacillus helveticus CNRZ 32, Nisin and Natamycin at Free State and Chitosan Nanoparticles-loaded state to become 6 treatments (T1 – T6) other than the control (C). The same treatments were applied to Karish cheese batches, in addition to inoculation of Lactobacillus helveticus CNRZ 32 1% (v/v) in the seventh batch. Upon microbiological analyses, results show that T2; the extract loaded on Chitosan Nanoparticles completely reduced the count of all pathogens and spoiling populations after two weeks of cold storage (2 – 6oC) in Talaga cheese. In the case of Karish cheese, the 7th batch treated with Lactobacillus helveticus CNRZ 32 inoculation had no pathogenic nor spoiler growth after one week of cold storage (2 – 6oC). These results suggest that Lactic acid bacteria especially Lactobacillus helveticus CNRZ 32 can efficiently ensure the safety and quality of cheese if applied in appropriate form.

show abstract

Section: Discussionmentioning

confidence: 98%

Application of Lactobacillus helveticus CNRZ 32 to Control the Microbial Contaminants in Cheese by Addition of Bacterial Extracts or by In Situ Production of Bioactive Metabolites

El-Sayad¹,

Ibrahim²,

Sharaf³

et al. 2021

AJC

View full text Add to dashboard Cite

show abstract

“…Similarly, Al Atya et al [27] demonstrated the synergetic activities of two class IIb bacteriocins, enterocins DD28 and DD93, associated with kanamycin and erythromycin against a clinical strain of MRSA. In direct line, the combinations of another bacteriocin, the lacticin 3147, with penicillin G or vancomycin and nisin z with methicillin, successfully inhibited the growth of MRSA strains [44]. Another synergistic effect of combining nisin A and cefazolin was reported against mastitis pathogens and also S. aureus, E. faecalis, Staphylococcus intermedius, Streptococcus agalactiae, Streptococcus dysgalactiae and Escherichia coli [45].…”

Section: Antibiotics and Bacteriocins Constitute Promising Synergistic Combinations For Medical Therapymentioning

confidence: 96%

Broadening and Enhancing Bacteriocins Activities by Association with Bioactive Substances

Zgheib

Drider

Belguesmia

2020

IJERPH

View full text Add to dashboard Cite

Bacteriocins are antimicrobial peptides some of which are endowed with antiviral, anticancer and antibiofilm properties. These properties could be improved through synergistic interactions of these bacteriocins with other bioactive molecules such as antibiotics, phages, nanoparticles and essential oils. A number of studies are steadily reporting the effects of these combinations as new and potential therapeutic strategies in the future, as they may offer many incentives over existing therapies. In particular, bacteriocins can benefit from combination with nanoparticles which can improve their stability and solubility, and protect them from enzymatic degradation, reduce their interactions with other molecules and improve their bioavailability. Furthermore, the combination of bacteriocins with other antimicrobials is foreseen as a way to reduce the development of antibiotic resistance due to the involvement of several modes of action. Another relevant advantage of these synergistic combinations is that it decreases the concentration of each antimicrobial component, thereby reducing their side effects such as their toxicity. In addition, combination can extend the utility of bacteriocins as antiviral or anticancer agents. Thus, in this review, we report and discuss the synergistic effects of bacteriocin combinations as medicines, and also for other diverse applications including, antiviral, antispoilage, anticancer and antibiofilms.

show abstract

“…This was demonstrated by a 100-fold reduction of MRSA-S1 biofilm cell numbers following treatment with Enterocins DD28 and DD93 in combination with kanamycin and erythromycin ( Al Atya et al, 2016 ). Ellis et al (2019) utilized sub-inhibitory concentrations of lacticin3147 to promote the dual effect of penicillin and vancomycin, resulting in the inhibition of various bacterial strains including MRSA. Similarly, this study examined the effects of nisin in combination with methicillin, which also produced impressive anti-MRSA activity ( Ellis et al, 2019 ).…”

Section: Bacteriocinsmentioning

confidence: 99%

“… Ellis et al (2019) utilized sub-inhibitory concentrations of lacticin3147 to promote the dual effect of penicillin and vancomycin, resulting in the inhibition of various bacterial strains including MRSA. Similarly, this study examined the effects of nisin in combination with methicillin, which also produced impressive anti-MRSA activity ( Ellis et al, 2019 ).…”

Section: Bacteriocinsmentioning

confidence: 99%

Efficacy of Phage- and Bacteriocin-Based Therapies in Combatting Nosocomial MRSA Infections

Walsh

Johnson

Hill

et al. 2021

Front. Mol. Biosci.

Self Cite

View full text Add to dashboard Cite

Staphylococcus aureus is a pathogen commonly found in nosocomial environments where infections can easily spread - especially given the reduced immune response of patients and large overlap between personnel in charge of their care. Although antibiotics are available to treat nosocomial infections, the increased occurrence of antibiotic resistance has rendered many treatments ineffective. Such is the case for methicillin resistant S. aureus (MRSA), which has continued to be a threat to public health since its emergence. For this reason, alternative treatment technologies utilizing antimicrobials such as bacteriocins, bacteriophages (phages) and phage endolysins are being developed. These antimicrobials provide an advantage over antibiotics in that many have narrow inhibition spectra, enabling treatments to be selected based on the target (pathogenic) bacterium while allowing for survival of commensal bacteria and thus avoiding collateral damage to the microbiome. Bacterial resistance to these treatments occurs less frequently than with antibiotics, particularly in circumstances where combinatory antimicrobial therapies are used. Phage therapy has been well established in Eastern Europe as an effective treatment against bacterial infections. While there are no Randomized Clinical Trials (RCTs) to our knowledge examining phage treatment of S. aureus infections that have completed all trial phases, numerous clinical trials are underway, and several commercial phage preparations are currently available to treat S. aureus infections. Bacteriocins have primarily been used in the food industry for bio-preservation applications. However, the idea of repurposing bacteriocins for human health is an attractive one considering their efficacy against many bacterial pathogens. There are concerns about the ability of bacteriocins to survive the gastrointestinal tract given their proteinaceous nature, however, this obstacle may be overcome by altering the administration route of the therapy through encapsulation, or by bioengineering protease-resistant variants. Obstacles such as enzymatic digestion are less of an issue for topical/local administration, for example, application to the surface of the skin. Bacteriocins have also shown impressive synergistic effects when used in conjunction with other antimicrobials, including antibiotics, which may allow antibiotic-based therapies to be used more sparingly with less resistance development. This review provides an updated account of known bacteriocins, phages and phage endolysins which have demonstrated an impressive ability to kill S. aureus strains. In particular, examples of antimicrobials with the ability to target MRSA strains and their subsequent use in a clinical setting are outlined.

show abstract

Nisin Z and Lacticin 3147 Improve Efficacy of Antibiotics Against Clinically Significant Bacteria

Cited by 27 publications

References 49 publications

Application of Lactobacillus helveticus CNRZ 32 to Control the Microbial Contaminants in Cheese by Addition of Bacterial Extracts or by In Situ Production of Bioactive Metabolites

Application of Lactobacillus helveticus CNRZ 32 to Control the Microbial Contaminants in Cheese by Addition of Bacterial Extracts or by In Situ Production of Bioactive Metabolites

Broadening and Enhancing Bacteriocins Activities by Association with Bioactive Substances

Efficacy of Phage- and Bacteriocin-Based Therapies in Combatting Nosocomial MRSA Infections

Contact Info

Product

Resources

About